Main Menu


Publications Highlights View all by category

Types of Publications

Journal Articles

Fenor de la Maza, M.D. Chandran, K. Rekowski, J. Shui, I.M. Gurel, B. Cross, E. Carreira, S. Yuan, W. Westaby, D. Miranda, S. Ferreira, A. Seed, G. Crespo, M. Figueiredo, I. Bertan, C. Gil, V. Riisnaes, R. Sharp, A. Rodrigues, D.N. Rescigno, P. Tunariu, N. Liu, X.Q. Cristescu, R. Schloss, C. Yap, C. de Bono, J.S. (2022). Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer. European urology oncology, .

Homer, V. Yap, C. Bond, S. Holmes, J. Stocken, D. Walker, K. Robinson, E.J. Wheeler, G. Brown, S. Hinsley, S. Schipper, M. Weir, C.J. Rantell, K. Prior, T. Yu, L.-. Kirkpatrick, J. Bedding, A. Gamble, C. Gaunt, P. (2022). Early phase clinical trials extension to guidelines for the content of statistical analysis plans. Bmj (clinical research ed.), Vol.376, pp. e068177-?.

Cruz Rivera, S. Aiyegbusi, O.L. Ives, J. Draper, H. Mercieca-Bebber, R. Ells, C. Hunn, A. Scott, J.A. Fernandez, C.V. Dickens, A.P. Anderson, N. Bhatnagar, V. Bottomley, A. Campbell, L. Collett, C. Collis, P. Craig, K. Davies, H. Golub, R. Gosden, L. Gnanasakthy, A. Haf Davies, E. von Hildebrand, M. Lord, J.M. Mahendraratnam, N. Miyaji, T. Morel, T. Monteiro, J. Zwisler, A.-. Peipert, J.D. Roydhouse, J. Stover, A.M. Wilson, R. Yap, C. Calvert, M.J. (2022). Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research: The PRO Ethics Guidelines. Jama, Vol.327 (19), pp. 1910-1919.  show abstract

Millen, G.C. Yap, C. (2021). Adaptive trial designs: what is the continual reassessment method?. Arch dis child educ pract ed, Vol.106 (3), pp. 175-177.

Cole, M. Yap, C. Buckley, C. Ng, W.F. McInnes, I. Filer, A. Siebert, S. Pratt, A. Isaacs, J.D. Stocken, D.D. (2021). TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis. Trials, Vol.22 (1), pp. 433-?.  show abstract

Silva, R.B. Yap, C. Carvajal, R. Lee, S.M. (2021). Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials. Jco precision oncology, (5), pp. 1024-1034.  show abstract

Wilson, N. Biggs, K. Bowden, S. Brown, J. Dimairo, M. Flight, L. Hall, J. Hockaday, A. Jaki, T. Lowe, R. Murphy, C. Pallmann, P. Pilling, M.A. Snowdon, C. Sydes, M.R. Villar, S.S. Weir, C.J. Welburn, J. Yap, C. Maier, R. Hancock, H. Wason, J.M. (2021). Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project. Bmc med, Vol.19 (1), pp. 251-?.  show abstract

Pallmann, P. Wan, F. Mander, A.P. Wheeler, G.M. Yap, C. Clive, S. Hampson, L.V. Jaki, T. (2020). Designing and evaluating dose-escalation studies made easy: The MoDEsT web app. Clin trials, Vol.17 (2), pp. 147-156.  show abstract

Tiu, C. Shinde, R. Yap, C. Rao Baikady, B. Banerji, U. Minchom, A.R. de Bono, J.S. Lopez, J.S. (2020). A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic. The lancet. oncology, Vol.21 (7), pp. 889-891.

Sharpe, E. Hoey, R. Yap, C. Workman, P. (2020). From patent to patient: analysing access to innovative cancer drugs. Drug discovery today, Vol.25 (9), pp. 1561-1568.  show abstract

Millen, G.C. Yap, C. (2020). Adaptive trial designs: what are multiarm, multistage trials?. Arch dis child educ pract ed, Vol.105 (6), pp. 376-378.

Pettitt, A.R. Jackson, R. Cicconi, S. Polydoros, F. Yap, C. Dodd, J. Bickerstaff, M. Stackpoole, M. Khan, U.T. Carruthers, S. Oates, M. Lin, K. Coupland, S.E. Menon, G. Kalakonda, N. McCarthy, H. Bloor, A. Schuh, A. Duncombe, A. Dearden, C. Fegan, C. Kennedy, B. Walewska, R. Marshall, S. Fox, C.P. Hillmen, P. (2020). Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial. Haematologica, .

Kong, A. Good, J. Kirkham, A. Savage, J. Mant, R. Llewellyn, L. Parish, J. Spruce, R. Forster, M. Schipani, S. Harrington, K. Sacco, J. Murray, P. Middleton, G. Yap, C. Mehanna, H. (2020). Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol. Bmj open, Vol.10 (3), p. e033009.  show abstract

Mergental, H. Laing, R.W. Kirkham, A.J. Perera, M.T. Boteon, Y.L. Attard, J. Barton, D. Curbishley, S. Wilkhu, M. Neil, D.A. Hübscher, S.G. Muiesan, P. Isaac, J.R. Roberts, K.J. Abradelo, M. Schlegel, A. Ferguson, J. Cilliers, H. Bion, J. Adams, D.H. Morris, C. Friend, P.J. Yap, C. Afford, S.C. Mirza, D.F. (2020). Transplantation of discarded livers following viability testing with normothermic machine perfusion. Nat commun, Vol.11 (1), p. 2939.  show abstract

Dimairo, M. Pallmann, P. Wason, J. Todd, S. Jaki, T. Julious, S.A. Mander, A.P. Weir, C.J. Koenig, F. Walton, M.K. Nicholl, J.P. Coates, E. Biggs, K. Hamasaki, T. Proschan, M.A. Scott, J.A. Ando, Y. Hind, D. Altman, D.G. ACE Consensus Group, (2020). The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials, Vol.21 (1), pp. 528-?.  show abstract

Craddock, C. Slade, D. De Santo, C. Wheat, R. Ferguson, P. Hodgkinson, A. Brock, K. Cavenagh, J. Ingram, W. Dennis, M. Malladi, R. Siddique, S. Mussai, F. Yap, C. (2019). Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.37 (7), pp. 580-588.  show abstract

Wason, J.M. Brocklehurst, P. Yap, C. (2019). When to keep it simple – adaptive designs are not always useful. Bmc medicine, Vol.17 (1).

O'Sullivan, J.M. Hamblin, A. Yap, C. Fox, S. Boucher, R. Panchal, A. Alimam, S. Dreau, H. Howard, K. Ware, P. Cross, N.C. McMullin, M.F. Harrison, C.N. Mead, A.J. (2019). The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. Blood, Vol.134 (23), pp. 2107-2111.

Wheeler, G.M. Mander, A.P. Bedding, A. Brock, K. Cornelius, V. Grieve, A.P. Jaki, T. Love, S.B. Odondi, L. Weir, C.J. Yap, C. Bond, S.J. (2019). How to design a dose-finding study using the continual reassessment method. Bmc medical research methodology, Vol.19 (1), pp. 18-?.  show abstract

Newsome, P.N. Fox, R. King, A.L. Barton, D. Than, N.-. Moore, J. Corbett, C. Townsend, S. Thomas, J. Guo, K. Hull, D. Beard, H.A. Thompson, J. Atkinson, A. Bienek, C. McGowan, N. Guha, N. Campbell, J. Hollyman, D. Stocken, D. Yap, C. Forbes, S.J. (2018). Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. The lancet. gastroenterology & hepatology, Vol.3 (1), pp. 25-36.  show abstract

Pratt, G. Yap, C. Oldreive, C. Slade, D. Bishop, R. Griffiths, M. Dyer, M.J. Fegan, C. Oscier, D. Pettitt, A. Matutes, E. Devereux, S. Allsup, D. Bloor, A. Hillmen, P. Follows, G. Rule, S. Moss, P. Stankovic, T. (2018). A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. British journal of haematology, Vol.182 (3), pp. 429-433.

Mergental, H. Stephenson, B.T. Laing, R.W. Kirkham, A.J. Neil, D.A. Wallace, L.L. Boteon, Y.L. Widmer, J. Bhogal, R.H. Perera, M.T. Smith, A. Reynolds, G.M. Yap, C. Hübscher, S.G. Mirza, D.F. Afford, S.C. (2018). Development of Clinical Criteria for Functional Assessment to Predict Primary Nonfunction of High-Risk Livers Using Normothermic Machine Perfusion. Liver transplantation : official publication of the american association for the study of liver diseases and the international liver transplantation society, Vol.24 (10), pp. 1453-1469.  show abstract

Pallmann, P. Bedding, A.W. Choodari-Oskooei, B. Dimairo, M. Flight, L. Hampson, L.V. Holmes, J. Mander, A.P. Odondi, L. Sydes, M.R. Villar, S.S. Wason, J.M. Weir, C.J. Wheeler, G.M. Yap, C. Jaki, T. (2018). Adaptive designs in clinical trials: why use them, and how to run and report them. Bmc medicine, Vol.16 (1), pp. 29-?.  show abstract

Love, S.B. Brown, S. Weir, C.J. Harbron, C. Yap, C. Gaschler-Markefski, B. Matcham, J. Caffrey, L. McKevitt, C. Clive, S. Craddock, C. Spicer, J. Cornelius, V. (2017). Embracing model-based designs for dose-finding trials. British journal of cancer, Vol.117 (3), pp. 332-339.  show abstract

Harrison, C.N. Mead, A.J. Panchal, A. Fox, S. Yap, C. Gbandi, E. Houlton, A. Alimam, S. Ewing, J. Wood, M. Chen, F. Coppell, J. Panoskaltsis, N. Knapper, S. Ali, S. Hamblin, A. Scherber, R. Dueck, A.C. Cross, N.C. Mesa, R. McMullin, M.F. (2017). Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood, Vol.130 (17), pp. 1889-1897.  show abstract

Yap, C. Billingham, L.J. Cheung, Y.K. Craddock, C. O'Quigley, J. (2017). Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making. Clinical cancer research : an official journal of the american association for cancer research, Vol.23 (24), pp. 7440-7447.  show abstract

Brock, K. Billingham, L. Copland, M. Siddique, S. Sirovica, M. Yap, C. (2017). Implementing the EffTox dose-finding design in the Matchpoint trial. Bmc medical research methodology, Vol.17 (1), pp. 112-?.  show abstract

Laing, R.W. Mergental, H. Yap, C. Kirkham, A. Whilku, M. Barton, D. Curbishley, S. Boteon, Y.L. Neil, D.A. Hübscher, S.G. Perera, M.T. Muiesan, P. Isaac, J. Roberts, K.J. Cilliers, H. Afford, S.C. Mirza, D.F. (2017). Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial. Bmj open, Vol.7 (11), pp. e017733-?.  show abstract

Bennett, H. Papadopoulou, E. Yap, C. (2016). Planar Minimization Diagrams via Subdivision with Applications to Anisotropic Voronoi Diagrams. Computer graphics forum, Vol.35 (5), pp. 229-247 (19).

Craddock, C. Jilani, N. Siddique, S. Yap, C. Khan, J. Nagra, S. Ward, J. Ferguson, P. Hazlewood, P. Buka, R. Vyas, P. Goodyear, O. Tholouli, E. Crawley, C. Russell, N. Byrne, J. Malladi, R. Snowden, J. Dennis, M. (2016). Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial. Biology of blood and marrow transplantation, Vol.22 (2), pp. 385-390.

Basu, S. Yap, C. Mason, S. (2016). Examining the sources of occupational stress in an emergency department. Occupational medicine (oxford, england), Vol.66 (9), pp. 737-742.  show abstract

King, A. Barton, D. Beard, H.A. Than, N. Moore, J. Corbett, C. Thomas, J. Guo, K. Guha, I. Hollyman, D. Stocken, D. Yap, C. Fox, R. Forbes, S.J. Newsome, P.N. (2015). REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis A study protocol for a randomised controlled trial. Bmj open, Vol.5 (3), pp. e007700-e007700.

Mussai, F.J. Yap, C. Mitchell, C. Kearns, P. (2014). Challenges of clinical trial design for targeted agents against pediatric leukemias. Front oncol, Vol.4, p. 374.  show abstract

Yap, C. Craddock, C. Collins, G. Khan, J. Siddique, S. Billingham, L. (2013). Implementation of adaptive dose-finding designs in two early phase haematological trials: clinical, operational, and methodological challenges. Trials, Vol.14 (S1).

Khan, J. Yap, C. Clark, R. Fenwick, N. Marin, D. (2013). Practical implementation of an adaptive phase I/II design in chronic myeloid leukaemia: evaluating both efficacy and toxicity using the EffTox design. Trials, Vol.14 (S1).

Yap, C. Pettitt, A. Billingham, L. (2013). Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia. Bmc medical research methodology, Vol.13 (1).

Beverland, I.J. Cohen, G.R. Heal, M.R. Carder, M. Yap, C. Robertson, C. Hart, C.L. Agius, R.M. (2012). A Comparison of Short-term and Long-term Air Pollution Exposure Associations with Mortality in Two Cohorts in Scotland. Environmental health perspectives, Vol.120 (9), pp. 1280-1285.

Beverland, I.J. Robertson, C. Yap, C. Heal, M.R. Cohen, G.R. Henderson, D.E. Hart, C.L. Agius, R.M. (2012). Comparison of models for estimation of long-term exposure to air pollution in cohort studies. Atmospheric environment, Vol.62, pp. 530-539.

Yap, C. Beverland, I.J. Heal, M.R. Cohen, G.R. Robertson, C. Henderson, D.E. Ferguson, N.S. Hart, C.L. Morris, G. Agius, R.M. (2012). Association between long-term exposure to air pollution and specific causes of mortality in Scotland. Occupational and environmental medicine, Vol.69 (12), pp. 916-924.

Yap, C. Billingham, L. Pettitt, A. (2011). Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia. Trials, Vol.12 (Suppl 1), pp. A91-A91.

Walji, N. Chue, A.L. Yap, C. Rogers, L.J. El-Modir, A. Chan, K.K. Singh, K. Fernando, I.N. (2010). Is There a Role for Adjuvant Hysterectomy after Suboptimal Concurrent Chemoradiation in Cervical Carcinoma?. Clinical oncology, Vol.22 (2), pp. 140-146.

Tho, L.M. McIntyre, A. Ross, A. Gallagher, C. Yap, C. Ritchie, D.M. Canney, P.A. (2006). Acute Supraclavicular Skin Toxicity in Patients Undergoing Radiotherapy for Breast Cancer: An Evaluation of the ‘T’-Grip Method of Patient Positioning. Clinical oncology, Vol.18 (2), pp. 133-138.

Tho, L.M. Glegg, M. Paterson, J. Yap, C. MacLeod, A. McCabe, M. McDonald, A.C. (2006). Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: Investigating dose–volume relationships and role for inverse planning. International journal of radiation oncology*biology*physics, Vol.66 (2), pp. 505-513.

Rhoney, D.H. Parker, D. Formea, C.M. Yap, C. Coplin, W.M. (2002). Tolerability of bolusversuscontinuous gastric feeding in brain-injured patients. Neurological research, Vol.24 (6), pp. 613-620.

Leung, E. Shenton, B.K. Jackson, G. Gould, F.K. Yap, C. Talbot, D. (2002). Use of real-time PCR to measure Epstein–Barr virus genomes in whole blood. Journal of immunological methods, Vol.270 (2), pp. 259-267.

Pratt, A.G. Siebert, S. Cole, M. Stocken, D.D. Yap, C. Kelly, S. Shaikh, M. Cranston, A. Morton, M. Walker, J. Frame, S. Ng, W.-. Buckley, C.D. McInnes, I.B. Filer, A. Isaacs, J.D. Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. The lancet. rheumatology, Vol.3 (5), pp. e337-e346.  show abstract

Pal, A. Stapleton, S. Yap, C. Lai-Kwon, J. Daly, R. Magkos, D. Baikady, B.R. Minchom, A. Banerji, U. De Bono, J. Karikios, D. Boyle, F. Lopez, J. Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT). Bmj open, Vol.11 (9), pp. e049217-e049217.  show abstract

Yap, C. Yin, Z. Minchom, A. Trends in Patient-Reported Outcome (PRO) use in Early Phase Dose-finding Oncology Trials (DFOT)- an Analysis of ClinicalTrials gov. Cancer medicine, .

Yap, C. Espinasse, A. Solovyeva, O. De Bono, J. The need for reporting guidelines for early phase dose-finding trials: Dose-Finding CONSORT Extension. Nature medicine, .

Fisher, B.A. Jonsson, R. Daniels, T. Bombardieri, M. Brown, R.M. Morgan, P. Bombardieri, S. Ng, W.-. Tzioufas, A.G. Vitali, C. Shirlaw, P. Haacke, E. Costa, S. Bootsma, H. Devauchelle-Pensec, V. Radstake, T.R. Mariette, X. Richards, A. Stack, R. Bowman, S.J. Barone, F. Sjögren's histopathology workshop group (appendix) from ESSENTIAL (EULAR Sjögren's syndrome study group), Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. Annals of the rheumatic diseases, Vol.76 (7), pp. 1161-1168.  show abstract

Copland, M. Slade, D. McIlroy, G. Horne, G. Byrne, J.L. Rothwell, K. Brock, K. De Lavallade, H. Craddock, C. Clark, R.E. Smith, M.L. Fletcher, R. Bishop, R. Milojkovic, D. Yap, C. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. The lancet haematology, .

Vanderbeek, A.M. Bliss, J.M. Yin, Z. Yap, C. Implementation of platform trials in the COVID-19 pandemic: A rapid review. Contemporary clinical trials, , pp. 106625-106625.

Yap, C. A Phase 1, Dose Escalation Study of Guadecitabine (SGI-110) in Combination with Pembrolizumab in Patients with Solid Tumours. Journal for immunotherapy of cancer, .

Yap, C. Personalized (N-of-1) Trials for Patient-Centered Treatments of Multimorbidity. Harvard data science review, .

Book Chapters

Brock, K. Billingham, L. Yap, C. Middleton, G. (2019). A Phase II Clinical Trial Design for Associated Co-primary Efficacy and Toxicity Outcomes with Baseline Covariates. Springer Proceedings in Mathematics & Statistics. (pp. 125-133). Springer International Publishing, ISBN: 9783030306106.

Mander, A.P. Wheeler, G.M. Yap, C. (2018). Practical Implementation of Dose–Response Adaptive Trials. Wiley StatsRef: Statistics Reference Online. (pp. 1-6). American Cancer Society, ISBN: 9781118445112.

Yap, C. Cheung, Y.K. (2018). Sequential Elimination in Multi-arm Multi-stage Selection Trials. Wiley StatsRef: Statistics Reference Online. (pp. 1-7). American Cancer Society, ISBN: 9781118445112.